Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine¹³¹-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma

References

• Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma:prognostic factors for response and survival. J Clin Oncol 1986;4:1470–1480.
   PubMed Web of Science ®Google Scholar
• Fisher RI. Overview of non-Hodgkin's lymphoma. Biology, staging and treatment. Semin Oncol 2003;30:3–9.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712–719.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352: 441–449.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918–3928.
   PubMed Web of Science ®Google Scholar
• Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316–1323.
   PubMed Web of Science ®Google Scholar
• Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2004;22:1469–1479.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259–1266.
   PubMed Web of Science ®Google Scholar
• Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004;10:7792–7798.
   PubMed Web of Science ®Google Scholar
• Buchegger F, Antonescu C, Delaloye AB, et al. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer 2006;94:1770–1776.
   PubMed Web of Science ®Google Scholar
• Buchegger F, Antonescu C, Helg C, et al. Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. J Nucl Med 2011; 52:896–900.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565–7573.
   PubMed Web of Science ®Google Scholar
• Product monograph: Bexxar® therapy (tositumomab and iodine I 131 tositumomab). Mississauga, ON: GlaxoSmithKline, Inc.; 20 Dec 2007.
   Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244–1253.
   Web of Science ®Google Scholar
• Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;1009: 1804–1810.
   Web of Science ®Google Scholar
• Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005;20:185–188.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140–147.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576–4582.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Gleissner B, Küppers R, Siebert R, et al. Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profiling. Br J Haematol 2008;142:166–178.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2:a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625–1638.
   PubMed Web of Science ®Google Scholar
• Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010;59:341–347.
   PubMed Web of Science ®Google Scholar
• Klaasen R, Cantaert T, Wijbrandts CA, et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis:an exploratory study. Rheumatology (Oxford) 2011;50:1487–1493.
   PubMed Web of Science ®Google Scholar
• Portugal RD. Obesity and dose individualization in cancer chemotherapy: the role of body surface area and body mass index. Med Hypotheses 2005;65:748–751.
   PubMed Web of Science ®Google Scholar
• Hunter RJ, Nano MA, Thaker PH, et al. Dosing chemotherapy in obese patients actual versus assigned body surface area (BSA). Cancer Treat Rev 2009;35:69–78.
   PubMed Web of Science ®Google Scholar